"Using the “scale-down to scale-up” approach requires running a lot more bench-scale fermentations in the short term to ultimately shorten your speed to market by mitigating scale-up risks in the long term."
"The biggest value of Culture, though, is having access to more bioreactor capacity: if we can do more runs, we can learn more. Running more bioreactors allows us to do more screening studies, do more robustness DoE studies, and it really supplements our internal capabilities."








